Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-21
2008-11-11
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S323000
Reexamination Certificate
active
07449474
ABSTRACT:
The present invention relates to 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.
REFERENCES:
patent: WO 99/23091 (1999-05-01), None
Robinson, Medical Therapy of Inflammatory Bowel Disease for the 21st Century, Eur J Surg 1998; Suppl 582, pp. 90-98.
Aleman et al., PubMed Abstract (Antivir Ther. 4(2):109-15), 1999.
Rasmussen, PubMed Abstract (Dan Med Bull. 47(2):94-114), 2000.
Green et al., PubMed Abstract (Immunol Rev 169:11-22), 1999.
Van Deventer, PubMed Abstract (Intensive Care Med. 26 Suppl 1:S98-102), 2000.
Holzheimer, PubMed Abstract (J Chemother. 13 Spec No. 1(1): 159-72), 2001.
Lesher, George Y., et al., “Novel orally active inhibitors of passive cutaneous anaphylaxis in rats: N-[2-(4-pyridinyl)-4-pyrimidinyl]ureas and dialkyl[[[2-(4-pyridinyl)-4-pyrimidinyl]amino]methyler,” Journal of Medical Chemistry, 25(7), 837-42. 1982, p. 841; Table IV.
Berberich Stephen Matthew
Bosch Gregory Kent
Brugel Todd Andrew
Clark Michael Philip
De Biswanath
McDow Kelly L.
Paul Andrew A.
Rao Deepak
The Procter & Gamble & Company
LandOfFree
Tri-substituted ureas as cytokine inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tri-substituted ureas as cytokine inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tri-substituted ureas as cytokine inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4049001